Exploring ribosome biogenesis in lung adenocarcinoma to advance prognostic methods and immunotherapy strategies
This study delves into the relationship between RiboSis and LUAD cell subpopulations, identifying a potent prognostic biomarker for LUAD. This biomarker aids in assessing immunotherapy efficacy in LUAD patients, ultimately enhancing their prognosis and guiding clinical decision-making.
Authors
- Jianan Zheng (ORCID: https://orcid.org/0009-0003-8268-0002)
- Xincen Cao
- Zhihua Li (ORCID: https://orcid.org/0000-0003-2003-5457)
- Liang Chen (ORCID: https://orcid.org/0000-0002-7985-4273)
- Pengpeng Zhang (ORCID: https://orcid.org/0000-0002-7149-0145)
- Yuheng Wang (ORCID: https://orcid.org/0000-0002-1786-5970)
- Jianwei Tang (ORCID: https://orcid.org/0000-0003-0176-5841)
- Xin Geng (ORCID: https://orcid.org/0009-0007-8743-7510)
- Miaolin Zhu
- Zipei Song
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s12967-025-06489-0
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Natural Science Foundation of China